Abiopharma

🔍 Myers Colleen Elizabeth (Executive)

Company: VISTEON CORP (VC)

Report Date: 2026-03-15

Detailed Transactions and Holdings:

• Acquired 93 shares of Common Stock (Direct)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 336.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 32 shares of Common Stock at $89.09 per share (Direct)
  Date: 2026-03-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 304.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 244 shares of Common Stock (Direct)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 548.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 72 shares of Common Stock at $89.09 per share (Direct)
  Date: 2026-03-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 476.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 337 shares of Common Stock (Direct)
  Date: 2026-03-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 813.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 97 shares of Common Stock at $89.09 per share (Direct)
  Date: 2026-03-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 716.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 93 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-15 | Code: M | Expires: 2026-03-15 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F3
• Sold 244 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-15 | Code: M | Expires: 2027-03-15 | equity_swap_involved: 0 | shares_owned_after: 245.00 | transaction_form_type: 4 | Footnotes: F1, F1, F3
• Sold 337 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-15 | Code: M | Expires: 2028-03-15 | equity_swap_involved: 0 | shares_owned_after: 672.00 | transaction_form_type: 4 | Footnotes: F1, F1, F3

Footnotes:

• F1: Each Restricted Stock Unit, which is the economic equivalent of one share of Visteon common stock, automatically vested on March 15, 2026 and was converted and paid to me in common stock without any election or action on my part. The value of each share was based on the fair market value of Visteon common stock as of March 13, 2026, the next preceding trading day, and one of the shares reflect dividend equivalents paid in additional shares pursuant to the terms of the Visteon Corporation 2020 Incentive Plan.
• F2: These shares were withheld by Visteon to satisfy income tax withholding obligations arising in connection with the vesting of certain Restricted Stock Units. The value of each share was based on the fair market value of Visteon common stock as of March 13, 2026, the next preceding trading day.
• F3: Restricted Stock Units vest to the extent of 33% of the units granted on the following March 15th of each year after the date of grant. Each Restricted Stock Unit will be converted and distributed to me, without payment, in stock upon vesting and based upon the then current market value of a share of Visteon common stock, subject to tax withholding.